The chief scientific officer at 23andMe is leaving his role at the consumer genetics company, four years after his arrival helped energize its move toward drug discovery.
Richard Scheller, a Genentech veteran, has joined the Palo Alto, Calif.-based BridgeBio (BBIO) as chairman of research and development, according to Securities and Exchange Commission filings. Scheller remains on 23andMe’s board of directors.
About the Author Reprints
